Skip to content
ChickenStockChickenStock
Research348340
Neuromeka logo

Neuromeka (348340) stock

KOSDAQ · Machinery

KRW 14,190-4.25%(-630)

As of Nov 16, 11:33 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-7.71x

Net loss — not comparable

P/B

8.23x

P/S

20.18x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 2.8 billion-KRW 5.3 billion-KRW 4.6 billion-17.9%
Q1 2026Consolidated · Filed May 14, 2026KRW 3 billion-KRW 4.3 billion-KRW 25.7 billion-5.7%
Q4 2025Consolidated · Filed Mar 19, 2026KRW 7.9 billion-KRW 3.5 billion-KRW 5.7 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 4.5 billion-KRW 3.2 billion-KRW 4.3 billion-28.2%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 3.4 billion-KRW 4.2 billion-KRW 4.6 billion-53.2%
Q1 2025Consolidated · Filed May 15, 2025KRW 3.2 billion-KRW 4 billion-KRW 7.3 billion-12.8%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 19, 2026KRW 19 billion-KRW 14.9 billion-KRW 22 billion-25.0%
FY2024Consolidated · Filed Aug 14, 2025KRW 25.3 billion-KRW 19 billion-KRW 16.8 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
4.74%
Of trading value on Nov 13, 2026
Short-sale value
KRW 130 million
Previous 20-day average 10.85%
Net short position
523,642 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
2,503,782 shares
As of Nov 13, 2026 · 10.70% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20264.74%KRW 130 million
Nov 12, 20266.98%KRW 110 million
Nov 11, 20262.17%KRW 50 million
Nov 10, 20263.51%KRW 60 million
Nov 9, 202613.10%KRW 260 million
Nov 6, 202618.27%KRW 460 million
Nov 5, 202617.94%KRW 570 million
Nov 4, 202613.85%KRW 360 million
Nov 3, 202619.38%KRW 470 million
Nov 2, 202612.49%KRW 300 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Neuromeka (348340) stock information

KOSDAQ

Neuromeka (348340) is listed on KOSDAQ. Its market capitalization is about KRW 332.2 billion. On trailing-twelve-month earnings the P/E ratio is -7.71, and the P/B ratio is 8.23. Return on equity is -106.7%. These figures are computed in-house from official filings and are reference information only.

Neuromeka — frequently asked questions

What is the P/E ratio of Neuromeka (348340)?
On a trailing-twelve-month basis, 348340 trades at a P/E ratio of -7.71. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Neuromeka?
348340 has a market capitalization of about KRW 332.2 billion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.